OS Therapies Incorporated launched the 14th biopharmaceutical company initial public offering in the US in 2024 on 31 July, selling 1.6 million shares at $4 each to gross $6.4m in the smallest IPO so far this year. The funding will be enough to support clinical development of its lead osteosarcoma drug candidate, advance its antibody-drug conjugate (ADC) platform and fund other drug discovery and development activities plus administrative expenses.
Rockville, MD- and New York-based OS Therapies took the title of smallest IPO of 2024 from Chromocell Therapeutics Corporation, which grossed $6.6m in its February offering. The year’s largest IPO was its first – CG Oncology, Inc.’s offering in January that eventually brought in $437m in gross proceeds